Vaxxinity, Inc. (VAXX)
USD 0.05
(200.0%)
USD 0.05
(200.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 30.94 Million USD | -30.03% |
| 2022 | 44.22 Million USD | 16.21% |
| 2021 | 38.05 Million USD | -72.33% |
| 2020 | 137.51 Million USD | 174.44% |
| 2019 | 50.1 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q4 | 30.94 Million USD | -8.38% |
| 2023 Q3 | 33.77 Million USD | -7.1% |
| 2023 Q1 | 39.39 Million USD | -10.91% |
| 2023 Q2 | 36.35 Million USD | -7.73% |
| 2023 FY | 30.94 Million USD | -30.03% |
| 2022 Q3 | 42.69 Million USD | 7.68% |
| 2022 Q1 | 34.87 Million USD | -8.36% |
| 2022 FY | 44.22 Million USD | 16.21% |
| 2022 Q4 | 44.22 Million USD | 3.57% |
| 2022 Q2 | 39.65 Million USD | 13.71% |
| 2021 Q3 | 292.28 Million USD | 3.02% |
| 2021 FY | 38.05 Million USD | -72.33% |
| 2021 Q1 | 25.52 Million USD | -81.44% |
| 2021 Q2 | 283.7 Million USD | 1011.49% |
| 2021 Q4 | 38.05 Million USD | -86.98% |
| 2020 Q4 | 137.51 Million USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 FY | 137.51 Million USD | 174.44% |
| 2019 FY | 50.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -541.331% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -1202.357% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 20.508% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 76.67% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -1013.494% |
| Better Therapeutics, Inc. | 23.84 Million USD | -29.788% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -273.539% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -210.24% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -17.484% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 2.64% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 55.433% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -289.449% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 35.682% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 80.331% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -782.612% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -45.347% |
| Molecular Templates, Inc. | 31.17 Million USD | 0.728% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -147.257% |
| NexImmune, Inc. | 5.08 Million USD | -508.627% |
| Orgenesis Inc. | 35.53 Million USD | 12.92% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -87.403% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -11515.005% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -1248.127% |
| Scopus BioPharma Inc. | 7.45 Million USD | -315.109% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 93.742% |
| Statera Biopharma, Inc. | 22.67 Million USD | -36.459% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -183.526% |
| Trevena, Inc. | 48.26 Million USD | 35.883% |
| Vaccinex, Inc. | 5.94 Million USD | -420.767% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -1472.089% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 19.36% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -1020.527% |